Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors

Core Insights - Microbot Medical Inc. is transitioning into a commercially focused company with the election of David J. Wilson to the Board of Directors, who has extensive experience in the endovascular devices market [1][3] - The company is preparing for the commercial launch of its LIBERTY® Endovascular Robotic System, expected in the second quarter of 2025 [3] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company aiming to improve care quality for patients and providers globally [4] - The company has developed the world's first single-use, fully disposable endovascular robotic system, designed to eliminate barriers to accessing advanced robotic systems [4] Leadership Background - David J. Wilson has over 30 years of global leadership experience in business strategy, operations, R&D, and product launches, including significant roles at Johnson and Johnson [2] - Prior to joining Microbot Medical, Wilson was the President of Global Plasma at Haemonetics Corporation and is currently the CEO of InnovHeart [2] Board Changes - Wilson replaces Yossi Bornstein, who served on the Board since before the company went public in 2016, with his term ending in December 2024 [4]